Cargando…

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB

Detalles Bibliográficos
Autores principales:	Bektaş, M., Eşkazan, A. E., Tiryaki, T. O., Mullai, R., Elverdi, T., Salihoğlu, A., Tiribelli, M., Ar, M. C., Öngören, S., Başlar, Z., Nalçaci, M., Soysal, T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431575/ http://dx.doi.org/10.1097/01.HS9.0000850448.44505.f6

Ejemplares similares

The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia
por: ESATOĞLU, Sinem Nihal, et al.
Publicado: (2021)

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades
por: Çokgezer, Simay, et al.
Publicado: (2022)

Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
por: Öngören, Şeniz, et al.
Publicado: (2017)

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience
por: Öngören, Seniz, et al.
Publicado: (2018)

PB1898: BONE MARROW APLASIA – A RARE COMPLICATION OF IMATINIB THERAPY IN CML PATIENTS: ABOUT A CASE
por: chawad, W., et al.
Publicado: (2022)

466 Skin lesions in febrile neutropenic patients
por: Yemisen, Mucahit, et al.
Publicado: (2014)

PB1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML).
por: Fernandez-Leyva, Harberth
Publicado: (2023)

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
por: Bouchakor Moussa, Y., et al.
Publicado: (2022)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options
por: Çetin, Güven, et al.
Publicado: (2014)

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic()
por: Küçükyurt, Selin, et al.
Publicado: (2022)

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
por: Şahin, Fahri, et al.
Publicado: (2013)

PB1903: TRIAL IN PROGRESS: A MULTICENTER, OPEN-LABEL, PHASE IB/II STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hijiya, N., et al.
Publicado: (2022)

PB1986: FIRST-LINE TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS IN A REAL-WORLD DATA SETTING IN LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study
por: Ozbalak, Murat, et al.
Publicado: (2013)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)

PB1904: TRIAL IN PROGRESS: A PHASE III STUDY OF ASCIMINIB VS AN INVESTIGATOR-SELECTED TKI IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
por: Hughes, T., et al.
Publicado: (2022)

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
por: Yalnız, Fevzi Fırat, et al.
Publicado: (2017)

Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence
por: Aydin, Seniz Ongoren, et al.
Publicado: (2011)

PB2214: CORRELATION BETWEEN HEMORRHAGIC EVENTS AND IPSET SCORE IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
por: Tosoni, Luca, et al.
Publicado: (2023)

Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

PB1983: RELATIONSHIP BETWEEN REGULAR MOLECULAR MONITORING AND TREATMENT OUTCOMES IN CML PATIENTS IN ARMENIA
por: Harutyunyan, Lusine, et al.
Publicado: (2023)

PB1981: EXPERIENCE OF FOUR LABORATORIES OF THE ITALIAN CML LABNET NETWORK IN THE USE OF THE CEPHEID CARTRIDGE SYSTEM
por: Izzo, Barbara, et al.
Publicado: (2023)

PB1964: COMPARISON OF CLINICO-HEMATOLOGICAL PARAMETERS AND MOLECULAR AND CYTOGENETIC RESPONSE OF TWO BCR-ABL FUSION TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB
por: Baraa, Laabidi, et al.
Publicado: (2023)

PB1906: IS THERE A PLACE FOR IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA CHRONIC PHASE: REAL LIFE DATA FROM UNIVERSITY CENTER AFTER LONG PERIOD OF FOLLOW-UP
por: Lekovic, D., et al.
Publicado: (2022)

The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients
por: Yemişen, Mücahit, et al.
Publicado: (2016)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
por: Zannier, Maria Elena, et al.
Publicado: (2023)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Arı, M. Cem, et al.
Publicado: (2012)

PB2223: CLINICOPATHOLOGICAL, CYTOGENETIC AND MOLECULAR CHARACTERISTICS OF PATIENTS WITH NON-CML MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER STUDY
por: Guntiboina, Vinay Anand, et al.
Publicado: (2023)

PB1892: IMATINIB RESISTANCE: THE ROLE OF PHARMACOGENETIC VARIABILITY IN A SOUTH AFRICAN COHORT
por: De Long, C., et al.
Publicado: (2022)

PB1963: PSYCHIATRIC DISORDERS AS A FIRST MANIFESTATION OF SPORADIC CREUTZFELDT-JACOB DISEASE IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB: UNUSUAL AND LIFE THREATENING ASSOCIATION
por: Smaili, Rachid, et al.
Publicado: (2023)

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB1858: INFLUENCE OF INFLAMMATION ON ANGIOGENIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Mitrović Ajtić, O., et al.
Publicado: (2022)

PB1899: OUTCOMES OF PATIENTS UNDERGOING TREATMENT FOR ACUTE MYELOID LEUKAEMIA SHOWING HIGH DEGREE OF PREDICTIVE ACCURACY ON THE EUROPEAN LEUKAEMIA NET (ELN) POST-REMISSION TREATMENT SCORE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fptnvck43fj0i300sg3h0ourfj